We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Global Diagnostic Labs Market Driven by Increased POCT Testing and Smart Portable Devices

By LabMedica International staff writers
Posted on 13 Sep 2022
Print article
Image: The global diagnostic labs market is projected to touch USD 515 billion by 2028 (Photo courtesy of Pexels)
Image: The global diagnostic labs market is projected to touch USD 515 billion by 2028 (Photo courtesy of Pexels)

Clinical diagnostics are beneficial for diagnosing prevalent chronic diseases and are valuable in disease prevention, detection, and treatment. Clinical diagnostics help identify early warning signs and individual risk factors, and create new opportunities for prevention and early intervention. As diagnostic chains and insurance coverage expand, clinical laboratory tests are becoming more common due to the increasing demand for early detection of diseases and earliest possible search for causes to receive appropriate therapy. Diagnostic laboratories, which are equipped with apparatus and reagents for performing diagnostic tests, play an important role in reducing the widespread impact of certain diseases. Hence, the increasing prevalence of chronic diseases, growing use of point-of-care diagnostics, and rising healthcare expenditures are fueling the growth of the diagnostic labs market. The global diagnostic labs market is projected grow at a CAGR of 8.3% from over USD 297 billion in 2021 to more than USD 514 billion by 2028.

These are the latest findings of Research and Markets (Dublin, Ireland), a market research firm.

The COVID-19 pandemic has led to increased funding and tests, which boosted the growth of the diagnostic labs market. Millions of tests were carried out worldwide to identify COVID-19 infection and stop the spread of the SARS-CoV-2 virus. Due to the increased burden of COVID-19 testing or drop in demand for other types of diagnostic tests, several laboratories had stopped performing other diagnostic procedures. Various testing laboratories entered the diagnostic labs market and significantly contributed to its further growth. Thus, the increasing number of SARS-CoV-2 tests due to a constant rise in COVID-19 infections and government funding is expected to result in a surge in demand for testing and propel the growth of the global diagnostic labs market.

Diagnostics laboratories have witnessed a digital transformation, and the modern laboratory has dramatically changed how tests are performed. As the technological revolution in labs continues, there is a growing need to provide a modern, quality-driven digital approach to laboratory operations that offers convenience, innovation, and reliability. Innovative technologies have made POCT devices portable and also improved sampling techniques, so they are minimally disruptive. POCT technology's relatively user-friendly nature is mainly due to advances in disposable test cartridges and microprocessor-based analyzers. Several such advances are poised to change the industry testing paradigm through greater speed, quality, efficiency, and scalability to better guide patient care.

The healthcare system is increasingly recognizing the value that labs can play by becoming more of a clinical decision-making engine, helping patients conduct tests at home and physicians interpreting results and diagnosing and monitoring patients more accurately and faster. The smart lab market includes proprietary robotic platforms, automated tools, software-as-a-service (SaaS), mobile apps, and other digital solutions that support operations, data management, and analytics across the entire value chain in diagnostic labs and promote the growth the diagnostic labs market.

The ecosystem to support the growth of smart labs is maturing, and several technology start-ups and prominent commercial players are already developing products and solutions targeting the specific areas for pre-and post-analytical surgeries and related areas, including smart procurement and remote monitoring, and predictive maintenance. Increasing testing volumes, cost pressures, and distributed labs are forcing traditional participants to leverage converging technologies such as robotics, Artificial Intelligence (AI), big data, Inter of Things (IoT), and cloud technologies to move from static, fragmented operations and tools to dynamic and value-driven practices, making diagnostic results more accurate and faster.

Related Links:
Research and Markets 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.